At Tuesday's close, Cingulate shares fell 4.99% to $3.62 and slipped further 1.66% to $3.56 in after-hours trading. According to the Kansas-based biotech, children who took CTx-1301 at doses of 18 ...

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application (NDA) for lead ADHD Asset CTx-1301 and Remains on Track to Submit the NDA Mid-2025 and Provides additional Clinical ...

The Kansas City, Kansas-based pharmaceutical startup has worked its way through a couple of delisting warnings from the Nasdaq stock exchange. Cingulate loses key execs, almost its entire board ...

(RTTNews) - Cingulate Inc. (CING) announced it was issued a European patent for lead asset CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder. The patent will include up to 30 ...

Cingulate Inc. CING shares are surging, trading over 159% higher today. Here’s what’s driving the movement. Why It’s Moving: Cingulate’s stock is soaring following the announcement that ...

Cingulate developed CTx-1301 using its precision timed release (PTR) drug delivery platform. The drug contains dexmethylphenidate , an FDA-approved stimulant used to treat ADHD. Patients with ADHD ...